Identification and Validation of a Novel Multiomics Signature for Prognosis and Immunotherapy Response of Endometrial Carcinoma

Figure 6

ARID1A mutation may interact with Treg and promote Type-I–IFN–Response pathway to facilitate tumor immune response in EC (endometrial cancer). (a) 71 DEGs (differentially expressed genes), 25 upregulated and 46 downregulated, between ARID1A mutant and wild group in UCEC (uterine corpus endometrial carcinoma) cohort. (b) KEGG and GO enrichment analysis of the 71 DEGs. (c-d) correlation between 25 upregulated genes/46 downregulated genes and abundances of 26 immune cells, respectively. (e) Regulating network between immune pathways (purple), tumor infiltrating cells (red), and DEGs (green). (UCEC : The Cancer Genome Atlas-Uterine Corpus Endometrial Carcinoma cohort; FDR : False Discovery Rate; KEGG : Kyoto Encyclopedia of Genes and Genomes; GO : Gene Ontology).

(a)

(b)

(c)

(d)

(e)